- Previous Close
0.3600 - Open
0.3600 - Bid 0.2649 x --
- Ask 0.3300 x --
- Day's Range
0.3600 - 0.3600 - 52 Week Range
0.1116 - 0.4328 - Volume
2,500 - Avg. Volume
7,402 - Market Cap (intraday)
35.552M - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
www.bionxt.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BNXTF
View MorePerformance Overview: BNXTF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNXTF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNXTF
View MoreValuation Measures
Market Cap
35.55M
Enterprise Value
39.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.11k
Price/Book (mrq)
--
Enterprise Value/Revenue
1.32k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-255.97%
Return on Equity (ttm)
--
Revenue (ttm)
42.01k
Net Income Avi to Common (ttm)
-6.48M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
80.06k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.72M